Volumetric Laser Endomicroscopy's (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management Study
Last updated on July 2021Recruitment
- Recruitment Status
- Enrolling by invitation
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Bile Duct Neoplasms
- Bile Duct Adenoma
- Bile Duct Cancer
- Pancreatic Duct Stricture
- Pancreatic Duct Obstruction
- Bile Duct Diseases
- Bile Duct Lesions
- Bile Duct Neoplasms Malignant
- Bile Duct Obstruction
- Bile Duct Obstruction, Extrahepatic
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Duct Stenosis
- Bile Duct Stenosi
- Pancreas Cancer
- Biliary Stricture
- Cholangiocarcinoma
- Primary Sclerosing Cholangitis
- Type
- Observational
- Design
- Observational Model: OtherTime Perspective: Retrospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Objective: Validate diagnostic impact of VLE diagnostic accuracy on clinical management Primary Objectives: Interobserver study for criteria validation and accuracy, Positive predictive value (PPV) and Negative predictive value (NPV), sensitivity and specificity. Evaluation of VLE diagnostics on cli...
Objective: Validate diagnostic impact of VLE diagnostic accuracy on clinical management Primary Objectives: Interobserver study for criteria validation and accuracy, Positive predictive value (PPV) and Negative predictive value (NPV), sensitivity and specificity. Evaluation of VLE diagnostics on clinical management (increased accuracy/faster detection) Determination of learning curve to standardize credentialing for endoscopists to use and interpret VLE imaging for biliary/pancreatic treatment management. B. Hypotheses / Research Question(s) The new VLE criteria for biliary and pancreatic duct strictures increase accuracy, thus leading to substantial impact on clinical management (Screening and Treatment) Study Design (2 phase): Phase 1: Primary Objective 1 and 2 part of the study will be completed. Phase 2: Primary Objective 3 of the study will be conducted within 1 month. Study Timeline: 3 months post WIRB approval. Sample size: 40 VLE Clips of at least 20 seconds featuring one or more the VLE criteria. All clips will have confirmed diagnosis for accuracy analysis. All clips will be de-identified. All clips will be removed from RedCAP and other secure cloud storage upon completion of study. Clips will be supplied by NinePoint Medical, the company behind VLE OCT. All VLE clips will be from a dataset of clips collected from adults > 18 and who underwent Endoscopic retrograde cholangiopancreatography (ERCP) with indeterminate biliary stricture indications. The clips are chosen based on the quality of the clips, duration, final diagnosis and presence of either benign or malignant criteria. Investigators: Up to 30 Expert and non-expert endoscopists currently using VLE
Tracking Information
- NCT #
- NCT03951324
- Collaborators
- NinePoint Medical
- Investigators
- Principal Investigator: Michel Kahaleh, MD Innovative Digestive Health Education and Research Inc